Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Goldenberg

Showing results (51-60 of 296) with videos related to

Pageof 30
Sort By:
Molecular Cancer Therapeutics|April 7, 2011
Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft modelsRobert M Sharkey, Habibe Karacay, Serengulam V Govindan, et al.
Molecular Cancer Research : MCR|June 18, 2009
Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell linesDavid E Modrak, Evelyn Leon, David M Goldenberg, et al.
Cancer|January 30, 2002
Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazineRhona Stein, Susan Chen, Linda Reed, et al.
Blood|July 15, 2010
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemiasPankaj Gupta, David M Goldenberg, Edmund A Rossi, et al.
Molecular Cancer Therapeutics|November 1, 2011
Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignanciesRobert M Sharkey, Serengulam V Govindan, Thomas M Cardillo, et al.
International Journal of Cancer|November 26, 2003
An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expressionRosalyn D Blumenthal, Evelyn Leone, David M Goldenberg, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 2, 2010
Improved cancer therapy and molecular imaging with multivalent, multispecific antibodiesRobert M Sharkey, Edmund A Rossi, Chien-Hsing Chang, et al.
Anti-Cancer Drugs|April 7, 2007
Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell linesJack D Burton, Mary E Castillo, David M Goldenberg, et al.
AIDS (London, England)|September 22, 2006
Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibodySusanne Johansson, David M Goldenberg, Gary L Griffiths, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell linesRhona Stein, Mitchell R Smith, Susan Chen, et al.
Pageof 30

Showing results (51-60 of 296) with videos related to

Sort By:
Pageof 30
Molecular Cancer Therapeutics|April 7, 2011
Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft modelsRobert M Sharkey, Habibe Karacay, Serengulam V Govindan, et al.
Molecular Cancer Research : MCR|June 18, 2009
Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell linesDavid E Modrak, Evelyn Leon, David M Goldenberg, et al.
Cancer|January 30, 2002
Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazineRhona Stein, Susan Chen, Linda Reed, et al.
Blood|July 15, 2010
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemiasPankaj Gupta, David M Goldenberg, Edmund A Rossi, et al.
Molecular Cancer Therapeutics|November 1, 2011
Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignanciesRobert M Sharkey, Serengulam V Govindan, Thomas M Cardillo, et al.
International Journal of Cancer|November 26, 2003
An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expressionRosalyn D Blumenthal, Evelyn Leone, David M Goldenberg, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 2, 2010
Improved cancer therapy and molecular imaging with multivalent, multispecific antibodiesRobert M Sharkey, Edmund A Rossi, Chien-Hsing Chang, et al.
Anti-Cancer Drugs|April 7, 2007
Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell linesJack D Burton, Mary E Castillo, David M Goldenberg, et al.
AIDS (London, England)|September 22, 2006
Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibodySusanne Johansson, David M Goldenberg, Gary L Griffiths, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell linesRhona Stein, Mitchell R Smith, Susan Chen, et al.
Pageof 30